Search results: Sage Journals

Open accessResearch articleFirst published 2026

Malignancy risk in patients with rheumatoid arthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a 5-year population-based cohort study

Chung-Mao Kao, Po-Cheng Shih, Der-Yuan Chen [...]

Therapeutic Advances in Musculoskeletal Disease

Open accessResearch articleFirst published 2025

Major adverse cardiovascular events or venous thromboembolism in patients with rheumatoid arthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a nationwide,population-based cohort study

Chung-Mao Kao, Yen-Ju Chen, Yi-Ming Chen [...]

Therapeutic Advances in Musculoskeletal Disease

Open accessResearch articleFirst published 2022

Predictive model to identify multiple failure to biological therapy in patients with rheumatoid arthritis

Marta Novella-Navarro, Diego Benavent, Virginia Ruiz-Esquide [...]

Therapeutic Advances in Musculoskeletal Disease

Open accessReview articleFirst published 2020

Immunosuppressive agents for rheumatoid arthritis: a systematic review of clinical trials and their current development stage

Julien Blaess, Julia Walther, Arthur Petitdemange [...]

Therapeutic Advances in Musculoskeletal Disease

Open accessReview articleFirst published 2024

Monotherapy or combination therapy in PsA: current aspects

Elpida Skouvaklidou, Paraskevi Avgerou, Konstantinos D. Vassilakis [...]

Therapeutic Advances in Musculoskeletal Disease

Restricted accessLetterFirst published December, 2023

Comparison of COVID-19 Vaccination and Infection Rates in Adult Patients With Autoimmune Inflammatory Disease on b/tsDMARD Therapy

Viktoriya Avlasevich, Katharine McCarthy

Annals of Pharmacotherapy

Open accessResearch articleFirst published 2022

Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry

Jung Hee Koh, Yusun Lee, Hyoun-Ah Kim [...]

Therapeutic Advances in Musculoskeletal Disease

Open accessResearch articleFirst published 2026

Incidence of interstitial lung disease in seropositive rheumatoid arthritis patients receiving biologics,Janus kinase inhibitors,or methotrexate

Jiyeol Yoon, Minkyung Han, Jason Jungsik Song [...]

Therapeutic Advances in Musculoskeletal Disease

Open accessResearch articleFirst published 2024

Switching related to inefficacy in biologics and targeted synthetic therapies for psoriatic arthritis: a comparative real-life study

Dalifer Freites-Nuñez, Leticia Leon, Esther Toledano [...]

Therapeutic Advances in Musculoskeletal Disease

Open accessReview articleFirst published 2020

Tuberculosis and targeted synthetic or biologic DMARDs,beyond tumor necrosis factor inhibitors

Gerasimos Evangelatos, Vasiliki Koulouri, Alexios Iliopoulos [...]

Therapeutic Advances in Musculoskeletal Disease

Open accessResearch articleFirst published 2026

Malignancy risk in patients with rheumatoid arthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a 5-year population-based cohort study

Chung-Mao Kao, Po-Cheng Shih, Der-Yuan Chen [...]

Therapeutic Advances in Musculoskeletal Disease

Open accessResearch articleFirst published 2025

Major adverse cardiovascular events or venous thromboembolism in patients with rheumatoid arthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a nationwide,population-based cohort study

Chung-Mao Kao, Yen-Ju Chen, Yi-Ming Chen [...]

Therapeutic Advances in Musculoskeletal Disease

Open accessResearch articleFirst published 2022

Predictive model to identify multiple failure to biological therapy in patients with rheumatoid arthritis

Marta Novella-Navarro, Diego Benavent, Virginia Ruiz-Esquide [...]

Therapeutic Advances in Musculoskeletal Disease

Open accessReview articleFirst published 2020

Immunosuppressive agents for rheumatoid arthritis: a systematic review of clinical trials and their current development stage

Julien Blaess, Julia Walther, Arthur Petitdemange [...]

Therapeutic Advances in Musculoskeletal Disease

Open accessReview articleFirst published 2024

Monotherapy or combination therapy in PsA: current aspects

Elpida Skouvaklidou, Paraskevi Avgerou, Konstantinos D. Vassilakis [...]

Therapeutic Advances in Musculoskeletal Disease

Restricted accessLetterFirst published December, 2023

Comparison of COVID-19 Vaccination and Infection Rates in Adult Patients With Autoimmune Inflammatory Disease on b/tsDMARD Therapy

Viktoriya Avlasevich, Katharine McCarthy

Annals of Pharmacotherapy

Open accessResearch articleFirst published 2022

Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry

Jung Hee Koh, Yusun Lee, Hyoun-Ah Kim [...]

Therapeutic Advances in Musculoskeletal Disease

Open accessResearch articleFirst published 2026

Incidence of interstitial lung disease in seropositive rheumatoid arthritis patients receiving biologics,Janus kinase inhibitors,or methotrexate

Jiyeol Yoon, Minkyung Han, Jason Jungsik Song [...]

Therapeutic Advances in Musculoskeletal Disease

Open accessResearch articleFirst published 2024

Switching related to inefficacy in biologics and targeted synthetic therapies for psoriatic arthritis: a comparative real-life study

Dalifer Freites-Nuñez, Leticia Leon, Esther Toledano [...]

Therapeutic Advances in Musculoskeletal Disease

Open accessReview articleFirst published 2020

Tuberculosis and targeted synthetic or biologic DMARDs,beyond tumor necrosis factor inhibitors

Gerasimos Evangelatos, Vasiliki Koulouri, Alexios Iliopoulos [...]

Therapeutic Advances in Musculoskeletal Disease